Novasep unveils new divisional structure

Related tags Groupe novasep Chemical engineering

Groupe Novasep has provided an update on the structural changes at
the company in the wake of its merger with Dynamic Synthesis in

The group will operate on the market as two distinct networks, called Novasep Synthesis and Novasep Process. The former will provide R&D services and custom synthesis, from the laboratory to industrial scale, with the combined expertise of the following business lines: Dynamit Nobel (specialized in hazardous chemistry), Rohner (transition metal catalysis), Finorga (experts in chiral chemistry) and Séripharm (specialized in high potency products).

Meanwhile, Novasep Process will offer research and purification solutions based on chromatography, ion exchange, membranes, crystallization and downstream bioprocesses, and its network will include Novasep SAS (chromatography and crystallisation solutions for pharmaceutical companies), Applexion (chromatography, ion exchange for the foods and biotech markets) and Orelis (specialising in cross-flow filtration).

Roger Marc-Nicoud, Groupe Novasep's president and founder, said the new structure would 'maximize synergies between the resources of the group, give customers access to all the resources of the group via a single local contact, and keep the local management empowered to ensure an entrepreneurial and reactive behaviour'.

"In the life science market today, customers demand higher purity levels, cost-efficient solutions, strict regulatory and operational controls and shorter times to market,"​ he said.

A new logo (pictured) has been designed to represent all the business lines and activities of the group.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more